Bookmark and Share

Compound Summary for: CID 71353

dapoxetine

Also known as: Dapoxetina; Dapoxetinum; 119356-77-3; Dapoxetinum [INN-Latin]; Dapoxetina [INN-Spanish]; Dapoxetine hydrochloride
Molecular Formula: C21H23NO   Molecular Weight: 305.41342   InChIKey: USRHYDPUVLEVMC-FQEVSTJZSA-N
Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in December 2004. In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions.   From: DrugBank
Show subcontent titlesTable of Contents
Identification
Related Records
show all 3 sub-sections (Related Compounds with Annotation, Related Compounds, Related Substances)
Literature
Patents
Biomolecular Interactions and Pathways
Biological Test Results
Classification
Chemical and Physical Properties
_ _